| Chen, Jian |
NCT03521986: Pain and Quality of Life After Mediastinal Tumor Resection by Subxiphoid and Intercostal VATS |
|
|
| Recruiting | 3 | 100 | RoW | Subxiphoid uniportal VATS, Intercostal uniportal VATS | Lei Jiang | Mediastinal Neoplasms, Thoracic Neoplasm, Thoracic Surgery | 10/23 | 10/23 | | |
NCT03523468: Curative Effect and Quality of Life Between Uniportal and Open Sleeve Lobectomy for Central Type Lung Cancer |
|
|
| Recruiting | 3 | 200 | RoW | uniportal sleeve lobectomy, open sleeve lobectomy | Lei Jiang, Shanghai Pulmonary Hospital, Shanghai, China | Video-Assisted Thoracic Surgery, Lung Cancer | 05/24 | 12/24 | | |
NCT06205927: Randomized Study of Carbon Ion Boost in Hypoxic Lesions for Locally Advanced Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 77 | RoW | Standard carbon ion beam radiotherapy, Carbon ion beam radiotherapy simultaneously dose boost | Jian Chen | Non-small Cell Lung Cancer | 12/24 | 12/26 | | |
NCT06186726: Clinical Study of Carbon Ion Radiotherapy Combined With Chemotherapy for Thymic Epithelial Tumors |
|
|
| Recruiting | 2 | 48 | RoW | carbon ion radiotherapy | Jian Chen | Carbon Ion Radiotherapy, Thymoma, Thymic Carcinoma, Radiotherapy, Chemotherapy | 12/26 | 12/29 | | |
NCT06311981: Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients |
|
|
| Recruiting | 2 | 29 | RoW | carbon ion radiotherapy, targeted therapy, single regimen chemotherapy in sequence with radiotherapy | Jian Chen | Non-small Cell Lung Cancer, Older People, Carbon Ion Radiotherapy, Radiotherapy Side Effect | 06/25 | 06/26 | | |
NCT06311955: Clinical Study of Postoperative Carbon Ion Radiotherapy for Thymus Tumor With Residual Tumor |
|
|
| Recruiting | 2 | 48 | RoW | Carbon ion radiotherapy, combined with platinum-based regimen | Jian Chen | Thymic Epithelial Tumor, Radiotherapy Side Effect, Carbon Ion Radiotheray, Heavy Ion Radiotherapy | 02/28 | 02/29 | | |
NCT06311968: The Clinical Study of Post-operative Proton Radiotherapy for Thymus Tumor |
|
|
| Recruiting | 2 | 55 | RoW | Proton radiotherapy, combined platinum based chemotherapy | Jian Chen | Thymus Epithelial Tumor, Proton Radiotherapy, Radiation Toxicity | 02/27 | 02/27 | | |
SPH5030-201, NCT06434597: A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients. |
|
|
| Recruiting | 2 | 60 | RoW | SPH5030 | Shanghai Pharmaceuticals Holding Co., Ltd | Biliary Tract or Colorectal Cancer With Her2-positive/Mutated | 12/26 | 12/26 | | |
NCT05613452: Carbon Ion Therapy for Peripheral Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 43 | RoW | Carbon ion beam radiotherapy | Shanghai Proton and Heavy Ion Center | Non-small Cell Lung Cancer | 01/25 | 01/26 | | |
NCT05715931: Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma |
|
|
| Recruiting | 2 | 30 | RoW | Toripalimab, Trastuzumab, 5-FU, leucovorin, docetaxel, oxaliplatin (FLOT) | Yu jiren | Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, HER2-positive Gastric Cancer | 03/25 | 03/28 | | |
NCT05729646: Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma |
|
|
| Recruiting | 2 | 90 | RoW | Toripalimab, Oxaliplatin, S1 | Yu jiren | Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Mismatch Repair Deficiency | 02/26 | 02/29 | | |
NCT05872685: Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-05) |
|
|
| Recruiting | 2 | 314 | RoW | S1, Oxaliplatin, Serplulimab, Placebo | Yu jiren | Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Proficient Mismatch Repair | 04/26 | 04/29 | | |
NCT05970627: Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma |
|
|
| Not yet recruiting | 2 | 30 | RoW | Toripalimab, Oxaliplatin, S1 | Yu jiren | Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Epstein-Barr Virus-Associated Gastric Carcinoma | 07/26 | 07/29 | | |
NCT05688488: Clinical Study of Curcumin in Preventing Postoperative Adhesion of Bilateral Vocal Cords |
|
|
| Recruiting | 1/2 | 100 | RoW | Curcumin, Mitomycin-C | Eye & ENT Hospital of Fudan University | Glottic Web of Larynx, Laryngeal Stenosis, Glottic Carcinoma, Laryngeal Leucoplakia, Laryngeal Polyp, Laryngeal Papilloma | 12/25 | 12/26 | | |
| Recruiting | 1 | 150 | RoW | GQ1005 | GeneQuantum Healthcare (Suzhou) Co., Ltd. | HER2 Expressing or Mutated Advanced Malignant Solid Tumors | 12/24 | 07/25 | | |
NCT06614686: U87 CAR-T in Patients With Advanced Head and Neck Tumors |
|
|
| Recruiting | 1 | 20 | RoW | U87 autologous CAR T-cell | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | Nasopharynx Cancer, Head and Neck Cancer | 10/26 | 12/27 | | |
NCT05685719: A Study to Evaluate the Relative Bioavailability of STI-1558 and the Effect of Itraconazole and Rifampin on the Pharmacokinetics of STI-1558 |
|
|
| Completed | 1 | 37 | RoW | STI-1558, Itraconazole, Rifampin | Zhejiang ACEA Pharmaceutical Co. Ltd. | COVID-19 Pneumonia | 03/23 | 11/23 | | |
NCT05627063: A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 169 | US, RoW | ABSK121-NX | Abbisko Therapeutics Co, Ltd | Solid Tumor | 03/25 | 06/25 | | |
| Recruiting | 1 | 54 | RoW | HF1K16 /Arm 45 mg/m², HF1K16 /Arm 90 mg/m², HF1K16 /Arm 120 mg/m², HF1K16 /Arm 160 mg/m², HF1K16 /Arm 120 mg or 180 mg | HighField Biopharmaceuticals Corporation, Tigermed Consulting Co., Ltd | Solid Tumor, Adult | 04/25 | 11/25 | | |
NCT05861895: A Clinical Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HF158K1 in Participants With HER-2 Positive or HER-2 Low Expression Advanced Solid Tumors |
|
|
| Recruiting | 1 | 84 | US | HF158K1 /Arm 2 mg/m², Infusion, HF158K1 /Arm 6 mg/m², HF158K1 /Arm 15 mg/m², HF158K1 /Arm 30 mg/m², HF158K1 /Arm 45 mg/m², HF158K1 /Arm 60 mg/m² | HighField Biopharmaceuticals Corporation | Solid Tumors, Adult | 04/25 | 12/25 | | |
NCT05827328: Explore the Optimal Surgical Timing for Lung Surgery and Mediastinal Surgery After COVID-19 Infection |
|
|
| Completed | N/A | 2000 | RoW | Observation | Shanghai Pulmonary Hospital, Shanghai, China | Thoracic Diseases, Thoracic Surgery | 06/23 | 06/23 | | |
NCT06340295: A Multicenter, Prospective Cohort Study of Preserved Ratio Impaired Spirometry(PRISm) in a Population |
|
|
| Recruiting | N/A | 2000 | RoW | | Peking University First Hospital, Shanxi Bethune Hospital, First Affiliated Hospital Xi'an Jiaotong University, Tianjin Medical University General Hospital, The First Hospital of Qinhuangdao, Shandong Provincial Hospital, Second Hospital of Jilin University, People's Hospital of Xinjiang Uygur Autonomous Region, MinDong Hospital of Ningde City | COPD | 05/26 | 05/26 | | |
| Recruiting | N/A | 150 | RoW | Consumer wearable device | Peking University First Hospital | COPD | 09/23 | 09/23 | | |
CHENJIAN1, NCT06126393: MRI Radiomics Combined With Pathomics on the Prediction of Molecular Classification and Prognosis of Endometrial Cancer |
|
|
| Not yet recruiting | N/A | 350 | RoW | next generation sequencing AND Immunohistochemical examination, Magnetic resonance examination | Fujian Cancer Hospital, Fujian Provincial Hospital, First Affiliated Hospital of Fujian Medical University, Gutian Hospital | Endometrial Neoplasms | 03/27 | 06/27 | | |
NCT06396143: Research on Intelligent Screening and Decision-making for Neoadjuvant Therapy in Locally Advanced Gastric Cancer Based on Multi-omics Integration |
|
|
| Recruiting | N/A | 120 | RoW | | Zhejiang University | Locally Advanced Gastric Carcinoma | 06/25 | 12/25 | | |
NCT06551675: Effect of Silkworm Pupa Tablets in Gastrointestinal Malignancies at Nutritional Risk Following Radical Surgery |
|
|
| Recruiting | N/A | 120 | RoW | Silkworm pupa tablets, Control product | Xiaosun Liu, MD | Nutritional Deficiency, Gastrointestinal Cancer, Frailty Syndrome | 11/25 | 11/25 | | |
NCT06140589: Exploring the Efficacy, Safety and Cost-effectiveness Analysis of Cadonilimab in the Treatment of Cervical Cancer |
|
|
| Recruiting | N/A | 200 | RoW | Cadonilimab | Fujian Cancer Hospital, Fujian Medical University Affiliated Nanping First Hospital, The First Hospital Affiliated to Fujian Medical University, Fujian Medical University Union Hospital, Gutian Hospital, Jiangxi Provincial Cancer Hospital, Shunde Women and Children's Hospital (Maternity and Child Healthcare Hospital of Shunde Foshan), Lianyungang Donghai County People's Hospital, Changsha Maternal and Child Health Hospital, Pingxiang Maternal and Child Health Hospital, Huinan County People's Hospital, People's Hospital Affiliated to Fujian University of Traditional Chinese Medicine | Cervical Cancer | 12/24 | 12/26 | | |
NCT04212494: Thrombus Aspiration in STEMI Patients With High Thrombus Burden |
|
|
| Recruiting | N/A | 3838 | RoW | Thrombus aspiration, PCI Alone | Guangdong Provincial People's Hospital, Zhongshan People's Hospital, Guangdong, China, Kaiping Central Hospital, The Second Affiliated Hospital of Shantou University Medical College, The Third Xiangya Hospital of Central South University, Sihui City People's Hospital, Shenzhen Baoan District Shiyan People's Hospital, People's Hospital of Nanxiong County, Yuebei People's Hospital, Weifang Medical University, Wuzhou Gongren Hospital, Dafeng Hospital of Chaoyang District in Shantou City, Shenzhen Baoan People's Hospital, Dongguan People's Hospital, Yangchun People's Hospital, Taishan People's Hospital, The Second People's Hospital of Foshan, Guangzhou Hospital of integrated Traditional and West Medicine, Guangning People's Hospital, Foshan Sanshui District People's Hospital, Qingyuan People's Hospital, Luhe County People's Hospital, People's Hospital of Xinjiang Uygur Autonomous Region, The Fourth People's Hospital of Chenzhou, People's Hospital of Dapu County, Shenzhen People's Hospital, Heyuan people's Hospital, Huaiji People's Hospital, People's Hospital of Yingde City, Qingyuan Hospital of Traditional Chinese Medicine Affiliated To Guangzhou University of Traditional Chinese Medicine, Zhongshan Hospital Of Traditional Chinese Medicine, The Third Affiliated Hospital of Guangzhou Medical University, Lianzhou People's Hospital, Lianping Xian Ren Ming Yi Yuan, Guangxi Zhuang Autonomous Region Nationalities Hospital, Liuzhou Municipal Liutie Central Hospital, Chen Zhou 3RD People's Hospital, Longgang District Central Hospital of Shenzhen, The Affiliated Shunde Hospital of Jinan University, Shenzhen Longhua District Central Hospital, Shantou Central Hospital, Tongxiang First People's Hospital, Bobai County People's Hospital, Guangxi, Meizhou Traditional Chinese Medicine Hospital, The Third Affiliated Hospital of Sun Yat-Sen University, Yuedong Hospital, Shenzhen Third People's Hospital, Yangjiang People's Hospital, Jiangmen Central Hospital, Eighth Affiliated Hospital, Sun Yat-sen University, The First People's Hospital of Kashgar Erea, First People's Hospital of Foshan, Zhaoqing Gaoyao People's Hospital, People's Hospital of Nanhai District, Foshan, The Second Affiliated Hospital of Dalian Medical University, Nanning Second People's Hospital, The Second People's Hospital of Nanhai District of Foshan, Shangyou People's Hospital | ST-segment Elevation Myocardial Infarction (STEMI) | 08/25 | 02/26 | | |
NCT04912401: the Efficacy and Safety of Etanercept （Yi Sai Pu) in Chinese Patients With Moderate-to-Severe Psoriasis |
|
|
| Recruiting | N/A | 100 | RoW | | Second Affiliated Hospital, School of Medicine, Zhejiang University | Psoriasis, Etanercept | 12/25 | 12/25 | | |
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System |
|
|
| Not yet recruiting | N/A | 2150 | RoW | Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy | Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Heart Disease | 01/26 | 01/28 | | |
REPAIR PERS-AF, NCT06098989: A Prospective Study of REPeat Ablation In Patients With Recurrent PERSistent Atrial Fibrillation: Pulmonary Vein Isolation vs. Adjunct Posterior Wall Isolation ( Study) |
|
|
| Not yet recruiting | N/A | 150 | NA | Radio frequency ablation | Haukeland University Hospital, St. Olavs Hospital, University Hospital of North Norway | Atrial Fibrillation, Persistent, Atrial Fibrillation Recurrent | 11/26 | 11/26 | | |
NCT05540821: Efficacy of Double Contrast-enhanced Ultrasound of Pelvic in Preoperative Evaluation of Deep Endometriosis |
|
|
| Recruiting | N/A | 156 | RoW | Hysterosalpingo-contrast sonography and sonoPODography | Shenzhen Second People's Hospital | Deep Endometriosis | 06/25 | 06/25 | | |
NCT05697926: Preclinical Research for Personalized TCR-T Therapy for Head and Neck Cancer |
|
|
| Recruiting | N/A | 100 | RoW | No intervention | Eye & ENT Hospital of Fudan University | Head and Neck Cancer | 12/25 | 06/26 | | |
| Liu, Jian Xiong |
| Not yet recruiting | 4 | 314 | RoW | Eldecalcitol capsules, Edirol, Alfacalcidol tablets, Calcium carbonate tablets | Chinese SLE Treatment And Research Group, Beijing Life oasis public service center | Rheumatoid Arthritis, Osteoporosis, Osteopenia | 12/25 | 03/26 | | |
NCT05433480: A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer |
|
|
| Active, not recruiting | 3 | 274 | RoW | BPI-16350, placebo, Fulvestrant | Betta Pharmaceuticals Co., Ltd. | Breast Cancer | 12/23 | 07/25 | | |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer |
|
|
| Active, not recruiting | 3 | 866 | Europe, Japan, US, RoW | Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219 | Eli Lilly and Company, Eli Lilly and Company | Breast Neoplasms, Neoplasm Metastasis | 06/24 | 08/27 | | |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
RC48-C006, NCT03500380: A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases |
|
|
| Active, not recruiting | 2/3 | 301 | RoW | RC48-ADC, RC48, Lapatinib, Capecitabine | RemeGen Co., Ltd. | Breast Neoplasms, Breast Diseases, Capecitabine, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, HER2-positive Advanced Breast With Liver Metastases | 07/24 | 12/24 | | |
NCT05744687: Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer |
|
|
| Recruiting | 2/3 | 374 | RoW | SPH4336 Tablets 400mg, SPH4336 Tablets Placebo | Shanghai Pharmaceuticals Holding Co., Ltd | Locally Advanced or Metastatic Breast Cancer | 05/25 | 05/25 | | |
NCT05621434: A Study to Evaluate Inetetamab + Pyrotinib + Chemotherapy in Previously Untreated HER2-Positive Metastatic Breast Cancer |
|
|
| Not yet recruiting | 2 | 63 | NA | Inetetamab, pyrotinib, chemotherapy, Inetetamab for injection, Pyrotinib maleate | Fujian Medical University | HER2-positive Recurrent/Metastatic Breast Cancer | 12/24 | 12/25 | | |
NCT04778839: Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors. |
|
|
| Recruiting | 1 | 98 | RoW | Paclitaxel Micelles for Injection, Paclitaxel injection | First Affiliated Hospital of Zhejiang University, Hangzhou Dihua Biotechnology Co., LTD. | Advanced Solid Tumors | 10/24 | 12/24 | | |
NCT04861779: A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies |
|
|
| Recruiting | 1 | 156 | RoW | HSK29116 | Haisco Pharmaceutical Group Co., Ltd. | Relapsed/Refractory B-Cell Malignancies | 08/23 | 10/23 | | |
NCT06462326: A Study to Compare the Effect of Omadacycline Versus Moxifloxacin in Healthy Adult Volunteers |
|
|
| Completed | 1 | 24 | RoW | Moxifloxacin Oral Tablet, Avelox, Omadacycline Oral Tablet, NUZYRA | Zai Lab (Hong Kong), Ltd. | Healthy Volunteer | 09/24 | 09/24 | | |
KYM901, NCT04805307: Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901 |
|
|
| Recruiting | 1 | 162 | RoW | CMG901 | Keymed Biosciences Co.Ltd | Advanced Solid Tumor, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Pancreatic Cancer | 05/24 | 10/24 | | |
| Recruiting | 1 | 54 | RoW | HF1K16 /Arm 45 mg/m², HF1K16 /Arm 90 mg/m², HF1K16 /Arm 120 mg/m², HF1K16 /Arm 160 mg/m², HF1K16 /Arm 120 mg or 180 mg | HighField Biopharmaceuticals Corporation, Tigermed Consulting Co., Ltd | Solid Tumor, Adult | 04/25 | 11/25 | | |
NCT04187469: Efficacy and Safety of Isoniazid, Rifampicin and Moxifloxacin for the Intensive Phase of Initial Therapy of PTB |
|
|
| Not yet recruiting | N/A | 286 | RoW | Moxifloxacin, Isoniazid, Rifampicin, Avelox, Myambutol, Nydrazid, Rifampin, Rifadin, Rifampicin,Isoniazid,Pyrazinamide,Ethambutol, Myambutol,Nydrazid,Rifampin,Rifadin | Fifth Affiliated Hospital, Sun Yat-Sen University | Pulmonary Tuberculosis | 02/23 | 02/24 | | |
IBBR, NCT03589924: Study to Compare the Safety of Immediate One-stage With Expander-Implant Two-stage Augmented With TiLoop® Bra(COSTA) |
|
|
| Active, not recruiting | N/A | 440 | RoW | Immediate IBBR+TiLoop®Bra, Immediate-delayed IBBR+TiLoop®Bra | Jiong Wu, First Hospital of China Medical University, Second Affiliated Hospital, School of Medicine, Zhejiang University, The First Affiliated Hospital with Nanjing Medical University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Breast Cancer | 04/23 | 09/24 | | |
MAGIC-MT, NCT04700345: Managing Non-acute Subdural Hematoma Using Liquid Materials：a Chinese Randomized Trial of MMA Treatment |
|
|
| Active, not recruiting | N/A | 722 | RoW | Onyx, Burr-hole, Medical Management | Huashan Hospital, Shanghai Municipal Health Commission, Shanghai Shen Kang Hospital Development Center | Subdural Hematoma, Non-acute | 08/23 | 06/24 | | |
| Recruiting | N/A | 2132 | RoW | caFFR, Coronary Angiography-Derived Fractional Flow Reserve, FFR, Fractional Flow Reserve | Peking University First Hospital, Rainmed Ltd., Suzhou, China | Coronary Artery Disease, Coronary Stenosis, Myocardial Ischaemia, Coronary Circulation, Stable Angina Pectoris, Unstable Angina Pectoris, Asymptomatic Ischemia, Acute Myocardial Infarction, Percutaneous Coronary Intervention | 12/23 | 12/25 | | |
| Not yet recruiting | N/A | 32 | RoW | ATRA, Toripalimab | First Affiliated Hospital of Zhejiang University, Shanghai Longfine Biotechnology Co., Ltd., TopAlliance | Triple-negative Breast Cancer | 04/26 | 04/26 | | |
NCT05649488: Evaluate the Safety and Efficacy of Intracoronary Lithotripsy Balloon Catheter and Intracoronary Lithotripsy Apparatus |
|
|
| Recruiting | N/A | 184 | RoW | Intracoronary lithotripsy balloon catheter and Intracoronary lithotripsy apparatus, Dragonfly Opstar Imaging Catheter | Shanghai Bluesail Boyuan Medical Technology Co., Ltd. | Coronary Artery Disease, Intravascular Lithotripsy | 12/24 | 09/25 | | |
NCT05760157: Mulltimodal Dynamic Risk Assessment Systems of Heart Failure in Patients With Myocardial Infarction. |
|
|
| Recruiting | N/A | 567 | RoW | Possible risk factors of heart failure | Jian Liu, Peking University Third Hospital, Beijing Anzhen Hospital, Navy General Hospital, Beijing, Beijing Luhe Hospital, Beijing Chao Yang Hospital | Heart Failure, Acute Myocardial Infarction | 12/25 | 12/25 | | |
| Wang, Xing |
NCT03270007: Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer Patients With Positive Lymph Node Residual Disease After Neoadjuvant Chemotherapy |
|
|
| Recruiting | 4 | 304 | RoW | Vinorelbine, Intensive treatment | Tao OUYANG | Primary Breast Cancer | 06/24 | 12/24 | | |
NCT05862337: Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence. |
|
|
| Recruiting | 3 | 480 | RoW | Anlotinib hydrochloride capsules, Penpulimab injection, Anlotinib hydrochloride capsules -matching placebo, Penpulimab injection -matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Hepatocellular Carcinoma | 08/24 | 12/26 | | |
| Han, Wei D |
NCT04937387: Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled Asthma |
|
|
| Completed | 3 | 359 | RoW | FF/VI, FF/UMEC/VI, ELLIPTA | GlaxoSmithKline | Asthma | 08/24 | 08/24 | | |
PLICTS, NCT04067505: Rivaroxaban for the Prevention of Deep Vein Thrombosis in Patients With Left Iliac Vein Compression - The Study |
|
|
| Recruiting | 3 | 224 | RoW | Rivaroxaban, Xarelto, Warfarin, coumadin, Nadroparin, Fraxiparin | Second Affiliated Hospital, School of Medicine, Zhejiang University, Sir Run Run Shaw Hospital, Huadong Hospital, Shanghai Zhongshan Hospital, Shanghai 5th People's Hospital, Yantai Yuhuangding Hospital, Anhui Provincial Hospital, Zhejiang Provincial People's Hospital, Zhejiang Hospital | May-Thurner Syndrome | 12/24 | 12/24 | | |
OCEAN, NCT05263934 / 2021-005726-15: Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) |
|
|
| Recruiting | 3 | 160 | Europe, Canada, Japan, US, RoW | Depemokimab, Mepolizumab, Placebo matching mepolizumab, Placebo matching depemokimab | GlaxoSmithKline | Eosinophilic Granulomatosis With Polyangiitis | 10/25 | 11/25 | | |
PRIME-HFrEF, NCT04992832: Multi-intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Heart Failure With Reduced Ejection Fraction（ Study） |
|
|
| Completed | 1/2 | 40 | RoW | human umbilical cord mesenchymal stem cells, human serum albumin | Shanghai East Hospital | Heart Failure, Systolic | 01/23 | 04/23 | | |
| Active, not recruiting | 1 | 12 | RoW | JV001 | Shanghai East Hospital, Shanghai Juvensis Therapeutics Biotechnology Company Limited | Heart Failure, Dilated Cardiomyopathy | 07/25 | 12/25 | | |
| Recruiting | N/A | 10000 | RoW | | Shanghai Jiao Tong University School of Medicine, The First Affiliated Hospital of Anhui Medical University, Anhui Provincial Hospital, First Affiliated Hospital Bengbu Medical College, LanZhou University, Henan Cancer Hospital, The First Affiliated Hospital of Zhengzhou University, The Second Affiliated Hospital of Harbin Medical University, First Affiliated Hospital of Harbin Medical University, Harbin Medical University, The First Hospital of Jilin University, Second Hospital of Jilin University, China-Japan Union Hospital, Jilin University, The First People's Hospital of Changzhou, Changzhou No.2 People's Hospital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China, The First People's Hospital of Taicang, Wuxi Second People's Hospital, Xuzhou Central Hospital, Second Affiliated Hospital of Suzhou University, Affiliated Hospital of Nantong University, The First People's Hospital of Nantong, The Affiliated Hospital of Xuzhou Medical University, Second Affiliated Hospital of Nanchang University, The First Affiliated Hospital of Nanchang University, Jiangxi Provincial People's Hopital, Shengjing Hospital, Baotou Central Hospital, Qinghai People's Hospital, Changzhi Medical College, The First Affiliated Hospital of Shanxi Medical University, Shanxi Provincial Cancer Hospital, First Affiliated Hospital Xi'an Jiaotong University, Eastern Hepatobiliary Surgery Hospital, Shanghai Fengxian District Central Hospital, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Zhongshan Hospital, Shanghai Pudong Hospital, Central Hospital of Minhang District, Shanghai, Putuo District People's Hospital of Shanghai, Xinhua (Chongming) Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Tianjin Medical University Cancer Hospital, First Affiliated Hospital of Xinjiang Medical University, The First Affiliated Hospital of Kunming Medical College, Yinzhou Hospital Affiliated to Medical School of Ningbo University, Shaoxing Second Hospital, Shaoxing People's Hospital, First Affiliated Hospital of Wenzhou Medical University, Sir Run Run Shaw Hospital, Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang Cancer Hospital, Huizhou Municipal Central Hospital, Ningbo No. 1 Hospital, People's Hospital of Hunan Province, Hainan People's Hospital, Taizhou Municipal Hospital, Xinghua City People's Hospital, Tongliao City Hospital, Jiangxi Provincial Cancer Hospital, Shandong Provincial Hospital, Qilu Hospital of Shandong University, The Affiliated Hospital of Qingdao University, Xijing Hospital | Gallbladder Neoplasms | 12/22 | 12/25 | | |
| Han, Guoping |
NCT04061278: A Multicenter, Prospective, Phase III Randomized Controlled Clinical Study for the Treatment of N2-3 Nasopharyngeal Carcinoma Patients |
|
|
| Recruiting | 3 | 246 | RoW | 4 cycles of Neoadjuvant Chemotherapy With Definitive Radiotherapy, 3 cycles of Neoadjuvant Chemotherapy With concurrent chemoradiotherapy | Second Affiliated Hospital, School of Medicine, Zhejiang University | Nasopharyngeal Carcinoma, Neoadjuvant Chemotherapy | 06/22 | 12/22 | | |
| FANG, Hongming |
| Recruiting | 1 | 54 | RoW | HF1K16 /Arm 45 mg/m², HF1K16 /Arm 90 mg/m², HF1K16 /Arm 120 mg/m², HF1K16 /Arm 160 mg/m², HF1K16 /Arm 120 mg or 180 mg | HighField Biopharmaceuticals Corporation, Tigermed Consulting Co., Ltd | Solid Tumor, Adult | 04/25 | 11/25 | | |
NCT05861895: A Clinical Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HF158K1 in Participants With HER-2 Positive or HER-2 Low Expression Advanced Solid Tumors |
|
|
| Recruiting | 1 | 84 | US | HF158K1 /Arm 2 mg/m², Infusion, HF158K1 /Arm 6 mg/m², HF158K1 /Arm 15 mg/m², HF158K1 /Arm 30 mg/m², HF158K1 /Arm 45 mg/m², HF158K1 /Arm 60 mg/m² | HighField Biopharmaceuticals Corporation | Solid Tumors, Adult | 04/25 | 12/25 | | |
SELECT-1, NCT04397432: Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Retrospective Study |
|
|
| Active, not recruiting | N/A | 878 | RoW | | Tian Xie, LinkDoc Technology (Beijing) Co. Ltd. | Carcinoma, Non-Small-Cell Lung | 04/23 | 03/26 | | |
| Jian, Chen |
NCT06044233: A Bioequivalence Trial of Fasting Single Oral STI-1558 Capsule in Healthy Chinese Subjects |
|
|
| Completed | 1 | 32 | RoW | STI-1558, An oral small molecule prodrug that effectively inhibits the SARS-CoV-2 main protease (Mpro). | Zhejiang ACEA Pharmaceutical Co. Ltd. | COVID-19 | 10/23 | 11/23 | | |
